The Experts below are selected from a list of 14508 Experts worldwide ranked by ideXlab platform

Clemens Heiser - One of the best experts on this subject based on the ideXlab platform.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, U Sommer, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Ulrich J. Sommer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years. Methods Patients with OSA and PAP failure qualified for the G-PMS by the absence of obesity class 2 an AHI between 15 and 65 events/h and absence of complete concentric collapse at the velum during drug-induced sleep endoscopy. Optional 2- and 3-year follow-ups after implantation were collected during routine clinical practice. We measured respiratory parameters such as apnea–hypopnea index (AHI) and oxygen desaturation index (ODI) and daytime sleepiness using the Epworth sleepiness scale (ESS) in a per protocol analysis. Usage was calculated from device-downloaded reports. Device-related complications were documented. Results Of the 60 original patients, 41 returned for 2-year follow-up, and 38 for 3 years. About 76% at 2 years and 68% at 3 years met the criterion of therapy success defined as an AHI below 15/h. The median AHI was reduced from 28.6/h (baseline) to 9.0/h (2 years) and 10.0/h (3 years); whereas median ODI decreased from 27.0 to 6.3/h (2 years), and 8.3/h (3 years). Median ESS improved from baseline 13 points to 4 (2 years) and 6 (3 years). Usage was stable at approximately 45 h per week at 2 and 3 years. Serious device-related adverse events were rare, with two-device explantation between 12 to 36 months postoperatively. Conclusions The German multi-center long-term outcomes compare favorably with previously published studies. Respiratory and sleepiness efficacy outcomes were sustained over 2 and 3 years, with a favorable safety profile, supporting the safety and efficacy of a chronic implantable therapy.

  • outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter german post Market Study
    Laryngoscope, 2018
    Co-Authors: Armin Steffen, Joachim T. Maurer, Benedikt Hofauer, Ulrich J. Sommer, Katrin Hasselbacher, Clemens Heiser
    Abstract:

    Objective/Hypothesis Upper airway stimulation (UAS) of the hypoglossal nerve has been implemented in the routine clinical practice for patients with moderate-to-severe obstructive sleep apnea (OSA) who could not adhere to continuous positive airway pressure. This Study reports objective and patient-reported outcome after 12 months of implantation. Study Design Multicenter prospective single-arm Study. Methods Consecutive patients who received the UAS system (Inspire Medical Systems, Inc., Minneapolis, Minnesota, Maple Grove, MN, U.S.A.) were enrolled in three German centers. Key Study exclusion criteria included body mass index > 35 kg/m2, apnea–hypopnea index (AHI)   65, or complete concentric collapse at the soft palate during sedated endoscopy. Data collection at 6- and 12-month visit include home sleep test and patient-reported outcome measures. Results Among the total of 60 participants, the median AHI reduced from 28.6 to 9.5 from baseline to 12 months. Patient-reported outcome measured in Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire both improved significantly from baseline to 12 months. The average usage time was 39.1 ± 14.9 hours per week among all participants based on recordings by the implanted device. One patient requested a removal of the device for cosmetic and other personal reasons and was completed without sequelae. Conclusion This Study supported that UAS is a safe and effective treatment option for patients with OSA in routine clinical practice. Level of Evidence 4. Laryngoscope, 2017

Armin Steffen - One of the best experts on this subject based on the ideXlab platform.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, U Sommer, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Ulrich J. Sommer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years. Methods Patients with OSA and PAP failure qualified for the G-PMS by the absence of obesity class 2 an AHI between 15 and 65 events/h and absence of complete concentric collapse at the velum during drug-induced sleep endoscopy. Optional 2- and 3-year follow-ups after implantation were collected during routine clinical practice. We measured respiratory parameters such as apnea–hypopnea index (AHI) and oxygen desaturation index (ODI) and daytime sleepiness using the Epworth sleepiness scale (ESS) in a per protocol analysis. Usage was calculated from device-downloaded reports. Device-related complications were documented. Results Of the 60 original patients, 41 returned for 2-year follow-up, and 38 for 3 years. About 76% at 2 years and 68% at 3 years met the criterion of therapy success defined as an AHI below 15/h. The median AHI was reduced from 28.6/h (baseline) to 9.0/h (2 years) and 10.0/h (3 years); whereas median ODI decreased from 27.0 to 6.3/h (2 years), and 8.3/h (3 years). Median ESS improved from baseline 13 points to 4 (2 years) and 6 (3 years). Usage was stable at approximately 45 h per week at 2 and 3 years. Serious device-related adverse events were rare, with two-device explantation between 12 to 36 months postoperatively. Conclusions The German multi-center long-term outcomes compare favorably with previously published studies. Respiratory and sleepiness efficacy outcomes were sustained over 2 and 3 years, with a favorable safety profile, supporting the safety and efficacy of a chronic implantable therapy.

  • outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter german post Market Study
    Laryngoscope, 2018
    Co-Authors: Armin Steffen, Joachim T. Maurer, Benedikt Hofauer, Ulrich J. Sommer, Katrin Hasselbacher, Clemens Heiser
    Abstract:

    Objective/Hypothesis Upper airway stimulation (UAS) of the hypoglossal nerve has been implemented in the routine clinical practice for patients with moderate-to-severe obstructive sleep apnea (OSA) who could not adhere to continuous positive airway pressure. This Study reports objective and patient-reported outcome after 12 months of implantation. Study Design Multicenter prospective single-arm Study. Methods Consecutive patients who received the UAS system (Inspire Medical Systems, Inc., Minneapolis, Minnesota, Maple Grove, MN, U.S.A.) were enrolled in three German centers. Key Study exclusion criteria included body mass index > 35 kg/m2, apnea–hypopnea index (AHI)   65, or complete concentric collapse at the soft palate during sedated endoscopy. Data collection at 6- and 12-month visit include home sleep test and patient-reported outcome measures. Results Among the total of 60 participants, the median AHI reduced from 28.6 to 9.5 from baseline to 12 months. Patient-reported outcome measured in Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire both improved significantly from baseline to 12 months. The average usage time was 39.1 ± 14.9 hours per week among all participants based on recordings by the implanted device. One patient requested a removal of the device for cosmetic and other personal reasons and was completed without sequelae. Conclusion This Study supported that UAS is a safe and effective treatment option for patients with OSA in routine clinical practice. Level of Evidence 4. Laryngoscope, 2017

Eduardo Castello - One of the best experts on this subject based on the ideXlab platform.

  • A Low-cost , Highly-Customizable Robotic Platform for Testing Mobile Sensor Networks in Indoor Lab Environments
    IEEE Conference on Robotics and Automation, 2015
    Co-Authors: Eduardo Castello
    Abstract:

    —Developing a mobile platform which can be useful for sensor network scientists is a challenging task. In this paper, we propose a low-cost, highly-customizable robotic mobile platform in order to test mobile sensor network algorithms within lab environments. Using 3D printing technology and user friendly electronics, we provide a useful tool for mobile networking community. This way, the community will have the opportunity to test their algorithms before the deployment in real sensor nodes. A brief Market Study about the mobile platforms field is given in the paper which reveals that current platforms are either more expensive or simply do not meet the requirements for our target scenario.

  • Demo : A Low-cost , Highly Customizable Robotic Platform for Testing Mobile Sensor Networks
    MobiHoc’15, 2015
    Co-Authors: Eduardo Castello, Y Sinan Hanay
    Abstract:

    Developing a mobile platform which can be useful for sensor network scientists is a challenging task. In this paper, we propose a low-cost, highly customizable robotic mobile platform in order to test mobile sensor network algorithms within lab environments. Using 3D printing technology and user friendly electronics, we provide a useful tool for mobile networking community. This way, the community will have the opportunity to test their algorithms before the deployment in real sensor nodes. A brief Market Study about the mobile platforms field is given in the paper which reveals that current platforms are either more expensive or simply do not meet the requirements for our target scenario.

Benedikt Hofauer - One of the best experts on this subject based on the ideXlab platform.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, U Sommer, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Ulrich J. Sommer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years. Methods Patients with OSA and PAP failure qualified for the G-PMS by the absence of obesity class 2 an AHI between 15 and 65 events/h and absence of complete concentric collapse at the velum during drug-induced sleep endoscopy. Optional 2- and 3-year follow-ups after implantation were collected during routine clinical practice. We measured respiratory parameters such as apnea–hypopnea index (AHI) and oxygen desaturation index (ODI) and daytime sleepiness using the Epworth sleepiness scale (ESS) in a per protocol analysis. Usage was calculated from device-downloaded reports. Device-related complications were documented. Results Of the 60 original patients, 41 returned for 2-year follow-up, and 38 for 3 years. About 76% at 2 years and 68% at 3 years met the criterion of therapy success defined as an AHI below 15/h. The median AHI was reduced from 28.6/h (baseline) to 9.0/h (2 years) and 10.0/h (3 years); whereas median ODI decreased from 27.0 to 6.3/h (2 years), and 8.3/h (3 years). Median ESS improved from baseline 13 points to 4 (2 years) and 6 (3 years). Usage was stable at approximately 45 h per week at 2 and 3 years. Serious device-related adverse events were rare, with two-device explantation between 12 to 36 months postoperatively. Conclusions The German multi-center long-term outcomes compare favorably with previously published studies. Respiratory and sleepiness efficacy outcomes were sustained over 2 and 3 years, with a favorable safety profile, supporting the safety and efficacy of a chronic implantable therapy.

  • outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter german post Market Study
    Laryngoscope, 2018
    Co-Authors: Armin Steffen, Joachim T. Maurer, Benedikt Hofauer, Ulrich J. Sommer, Katrin Hasselbacher, Clemens Heiser
    Abstract:

    Objective/Hypothesis Upper airway stimulation (UAS) of the hypoglossal nerve has been implemented in the routine clinical practice for patients with moderate-to-severe obstructive sleep apnea (OSA) who could not adhere to continuous positive airway pressure. This Study reports objective and patient-reported outcome after 12 months of implantation. Study Design Multicenter prospective single-arm Study. Methods Consecutive patients who received the UAS system (Inspire Medical Systems, Inc., Minneapolis, Minnesota, Maple Grove, MN, U.S.A.) were enrolled in three German centers. Key Study exclusion criteria included body mass index > 35 kg/m2, apnea–hypopnea index (AHI)   65, or complete concentric collapse at the soft palate during sedated endoscopy. Data collection at 6- and 12-month visit include home sleep test and patient-reported outcome measures. Results Among the total of 60 participants, the median AHI reduced from 28.6 to 9.5 from baseline to 12 months. Patient-reported outcome measured in Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire both improved significantly from baseline to 12 months. The average usage time was 39.1 ± 14.9 hours per week among all participants based on recordings by the implanted device. One patient requested a removal of the device for cosmetic and other personal reasons and was completed without sequelae. Conclusion This Study supported that UAS is a safe and effective treatment option for patients with OSA in routine clinical practice. Level of Evidence 4. Laryngoscope, 2017

Joachim T. Maurer - One of the best experts on this subject based on the ideXlab platform.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, U Sommer, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years.

  • Long-term follow-up of the German post-Market Study for upper airway stimulation for obstructive sleep apnea
    Sleep and Breathing, 2019
    Co-Authors: Armin Steffen, Joachim T. Maurer, N Abrams, Benedikt Hofauer, Ulrich J. Sommer, Clemens Heiser
    Abstract:

    Purpose Upper airway stimulation (UAS) is an effective treatment for obstructive sleep apnea (OSA) in positive airway pressure (PAP) failure. Most reports have presented short-term data, so long-term safety and efficacy reports are rare. The German post-Market Study (G-PMS) has followed approximately 60 patients from three implanting centers for several years. Methods Patients with OSA and PAP failure qualified for the G-PMS by the absence of obesity class 2 an AHI between 15 and 65 events/h and absence of complete concentric collapse at the velum during drug-induced sleep endoscopy. Optional 2- and 3-year follow-ups after implantation were collected during routine clinical practice. We measured respiratory parameters such as apnea–hypopnea index (AHI) and oxygen desaturation index (ODI) and daytime sleepiness using the Epworth sleepiness scale (ESS) in a per protocol analysis. Usage was calculated from device-downloaded reports. Device-related complications were documented. Results Of the 60 original patients, 41 returned for 2-year follow-up, and 38 for 3 years. About 76% at 2 years and 68% at 3 years met the criterion of therapy success defined as an AHI below 15/h. The median AHI was reduced from 28.6/h (baseline) to 9.0/h (2 years) and 10.0/h (3 years); whereas median ODI decreased from 27.0 to 6.3/h (2 years), and 8.3/h (3 years). Median ESS improved from baseline 13 points to 4 (2 years) and 6 (3 years). Usage was stable at approximately 45 h per week at 2 and 3 years. Serious device-related adverse events were rare, with two-device explantation between 12 to 36 months postoperatively. Conclusions The German multi-center long-term outcomes compare favorably with previously published studies. Respiratory and sleepiness efficacy outcomes were sustained over 2 and 3 years, with a favorable safety profile, supporting the safety and efficacy of a chronic implantable therapy.

  • outcome after one year of upper airway stimulation for obstructive sleep apnea in a multicenter german post Market Study
    Laryngoscope, 2018
    Co-Authors: Armin Steffen, Joachim T. Maurer, Benedikt Hofauer, Ulrich J. Sommer, Katrin Hasselbacher, Clemens Heiser
    Abstract:

    Objective/Hypothesis Upper airway stimulation (UAS) of the hypoglossal nerve has been implemented in the routine clinical practice for patients with moderate-to-severe obstructive sleep apnea (OSA) who could not adhere to continuous positive airway pressure. This Study reports objective and patient-reported outcome after 12 months of implantation. Study Design Multicenter prospective single-arm Study. Methods Consecutive patients who received the UAS system (Inspire Medical Systems, Inc., Minneapolis, Minnesota, Maple Grove, MN, U.S.A.) were enrolled in three German centers. Key Study exclusion criteria included body mass index > 35 kg/m2, apnea–hypopnea index (AHI)   65, or complete concentric collapse at the soft palate during sedated endoscopy. Data collection at 6- and 12-month visit include home sleep test and patient-reported outcome measures. Results Among the total of 60 participants, the median AHI reduced from 28.6 to 9.5 from baseline to 12 months. Patient-reported outcome measured in Epworth Sleepiness Scale and Functional Outcomes of Sleep Questionnaire both improved significantly from baseline to 12 months. The average usage time was 39.1 ± 14.9 hours per week among all participants based on recordings by the implanted device. One patient requested a removal of the device for cosmetic and other personal reasons and was completed without sequelae. Conclusion This Study supported that UAS is a safe and effective treatment option for patients with OSA in routine clinical practice. Level of Evidence 4. Laryngoscope, 2017